The evolving place of vagus nerve stimulation therapy

Steven C. Schachter, James Wheless

Research output: Contribution to journalShort survey

20 Citations (Scopus)

Abstract

Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.

Original languageEnglish (US)
JournalNeurology
Volume59
Issue number6 SUPPL. 4
StatePublished - Sep 24 2002
Externally publishedYes

Fingerprint

Vagus Nerve Stimulation
Seizures
Therapeutics
United States Food and Drug Administration
Epilepsy

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

The evolving place of vagus nerve stimulation therapy. / Schachter, Steven C.; Wheless, James.

In: Neurology, Vol. 59, No. 6 SUPPL. 4, 24.09.2002.

Research output: Contribution to journalShort survey

Schachter, SC & Wheless, J 2002, 'The evolving place of vagus nerve stimulation therapy', Neurology, vol. 59, no. 6 SUPPL. 4.
Schachter, Steven C. ; Wheless, James. / The evolving place of vagus nerve stimulation therapy. In: Neurology. 2002 ; Vol. 59, No. 6 SUPPL. 4.
@article{f78f27c49d3940a5884bb8c03a5b20f7,
title = "The evolving place of vagus nerve stimulation therapy",
abstract = "Approximately 40{\%} of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.",
author = "Schachter, {Steven C.} and James Wheless",
year = "2002",
month = "9",
day = "24",
language = "English (US)",
volume = "59",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL. 4",

}

TY - JOUR

T1 - The evolving place of vagus nerve stimulation therapy

AU - Schachter, Steven C.

AU - Wheless, James

PY - 2002/9/24

Y1 - 2002/9/24

N2 - Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.

AB - Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.

UR - http://www.scopus.com/inward/record.url?scp=0037167559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037167559&partnerID=8YFLogxK

M3 - Short survey

VL - 59

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6 SUPPL. 4

ER -